0001125345-26-000017
SEC filingMacroGenics, Inc. reported a net loss of $74.6 million for fiscal year 2025, driven by an operating loss of $72.8 million. Total revenues were $149.5 million, while total costs and expenses amounted to $222.3 million, with research and development costs of $147.2 million representing the largest expense category. The company's cash position declined by $125.6 million during the year, ending with $108.9 million in cash and cash equivalents, supported by $69.5 million in net cash from financing activities primarily from the sale of future royalties. The balance sheet shows total assets of $256.8 million against total liabilities of $201.3 million, resulting in stockholders' equity of $55.6 million. The company continues to operate at a loss while maintaining significant investment in research and development activities.
MacroGenics, Inc. reported financial results for fiscal year 2025 ending December 31, 2025. The company generated total revenues of $149.5 million while incurring total costs and expenses of $222.3 million, resulting in an operating loss of $72.8 million. After accounting for interest and other income of $6.1 million, interest and other expense of $8.5 million, and an income tax benefit of $672,000, the company reported a net loss of $74.6 million. The comprehensive loss was also $74.6 million, with an unrealized gain on investments of $28,000. Basic and diluted net loss per common share was $1.00, based on 63.2 million weighted average common shares outstanding.
The company reported total revenues of $149.5 million for fiscal year 2025. The XBRL data does not provide segment breakdown or geographic mix information. The revenue sources are not detailed in the provided data beyond the aggregate total revenue figure. No specific growth drivers or product/service breakdowns are disclosed in the available information.
The company operated at a loss for fiscal year 2025 with negative operating income of $72.8 million. Research and development expenses of $147.2 million represented the largest cost component, followed by selling, general and administrative expenses of $39.2 million and cost of manufacturing services of $36.0 million. The company had no cost of product sales. The operating loss margin was 48.7% of total revenues. No gross profit or gross margin figures are provided in the XBRL data.
The company used $81.0 million in cash from operating activities during fiscal year 2025, primarily driven by the net loss of $74.6 million. Investing activities used $114.1 million, mainly for purchases of marketable securities of $208.3 million, partially offset by proceeds from sales and maturities of marketable securities of $96.1 million. Financing activities provided $69.5 million, primarily from net proceeds from sale of future royalties of $69.7 million. The net change in cash and cash equivalents was a decrease of $125.6 million. The balance sheet shows total assets of $256.8 million, including current assets of $219.9 million with cash and cash equivalents of $57.2 million and marketable securities of $132.7 million. Total liabilities were $201.3 million, including a liability related to future royalties of $70.0 million. Stockholders' equity was $55.6 million.
The provided XBRL data and document content do not include management guidance, strategic priorities, or specific risk factors for future periods. No forward-looking statements or outlook information is available in the provided financial data sections. The analysis is limited to the historical financial results for fiscal year 2025 as presented in the XBRL data.